XNCR – Xencor Inc
Xencor, Inc.XNCR
$15.74Name : Xencor, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,101,516,672.00
EPSttm : -3.18
Xencor, Inc.
$15.74
0.32%$0.05Float Short %
7.99
Margin Of Safety %
-11
Put/Call OI Ratio
1.33
EPS Next Q Diff
-0.12
EPS Last/This Y
EPS This/Next Y
0.6
Price
15.74
Target Price
32.91
Analyst Recom
1.33
Performance Q
-32.13
Relative Volume
0.74
Beta
0.72
Ticker: XNCR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | XNCR | 20.45 | 0.71 | 0.00 | 186 |
| 2025-01-24 | XNCR | 19.65 | 0.71 | 0.00 | 186 |
| 2025-01-27 | XNCR | 19.18 | 0.71 | 0.00 | 186 |
| 2025-01-28 | XNCR | 19.32 | 0.71 | 0.00 | 186 |
| 2025-01-29 | XNCR | 18.84 | 0.70 | 0.00 | 187 |
| 2025-01-30 | XNCR | 18.52 | 0.67 | 999.99 | 192 |
| 2025-01-31 | XNCR | 18.28 | 0.70 | 3.50 | 196 |
| 2025-02-03 | XNCR | 17.63 | 0.70 | 3.50 | 196 |
| 2025-02-04 | XNCR | 17.74 | 0.74 | 1.50 | 204 |
| 2025-02-05 | XNCR | 17.5 | 0.73 | 0.00 | 206 |
| 2025-02-06 | XNCR | 17.25 | 0.73 | 2.00 | 206 |
| 2025-02-07 | XNCR | 17.05 | 0.79 | 0.00 | 220 |
| 2025-02-10 | XNCR | 16.86 | 0.78 | 999.99 | 221 |
| 2025-02-11 | XNCR | 16.12 | 1.27 | 5.00 | 281 |
| 2025-02-12 | XNCR | 16.24 | 1.27 | 5.00 | 281 |
| 2025-02-13 | XNCR | 16.29 | 1.27 | 5.00 | 281 |
| 2025-02-14 | XNCR | 16.32 | 1.27 | 5.00 | 281 |
| 2025-02-18 | XNCR | 16.22 | 1.33 | 0.00 | 293 |
| 2025-02-19 | XNCR | 16.2 | 1.33 | 0.00 | 293 |
| 2025-02-20 | XNCR | 15.77 | 1.33 | 0.00 | 293 |
| 2025-02-21 | XNCR | 15.74 | 1.33 | 0.00 | 293 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | XNCR | 20.46 | -153.6 | - | -3.68 |
| 2025-01-24 | XNCR | 19.62 | -153.6 | - | -3.68 |
| 2025-01-27 | XNCR | 19.23 | -153.6 | - | -3.68 |
| 2025-01-28 | XNCR | 19.32 | -153.6 | - | -3.68 |
| 2025-01-29 | XNCR | 18.83 | -153.6 | - | -3.68 |
| 2025-01-30 | XNCR | 18.50 | -153.6 | - | -3.68 |
| 2025-01-31 | XNCR | 18.28 | -153.6 | - | -3.68 |
| 2025-02-03 | XNCR | 17.62 | -153.6 | - | -3.68 |
| 2025-02-04 | XNCR | 17.76 | -153.6 | - | -3.68 |
| 2025-02-05 | XNCR | 17.51 | -153.6 | - | -3.68 |
| 2025-02-06 | XNCR | 17.24 | -153.6 | - | -3.68 |
| 2025-02-07 | XNCR | 17.06 | -153.6 | - | -3.68 |
| 2025-02-10 | XNCR | 16.83 | -153.6 | - | -3.68 |
| 2025-02-11 | XNCR | 16.14 | -153.6 | - | -3.68 |
| 2025-02-12 | XNCR | 16.25 | -153.6 | - | -3.68 |
| 2025-02-13 | XNCR | 16.29 | -153.6 | - | -3.68 |
| 2025-02-14 | XNCR | 16.31 | -153.6 | - | -3.68 |
| 2025-02-18 | XNCR | 16.23 | -153.6 | - | -3.68 |
| 2025-02-19 | XNCR | 16.20 | -153.6 | - | -3.68 |
| 2025-02-20 | XNCR | 15.79 | -153.6 | - | -3.68 |
| 2025-02-21 | XNCR | 15.74 | -153.6 | - | -3.68 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | XNCR | -3.54 | 18.42 | 7.58 |
| 2025-01-24 | XNCR | -3.54 | 18.42 | 7.58 |
| 2025-01-27 | XNCR | -3.54 | 18.26 | 7.58 |
| 2025-01-28 | XNCR | -3.54 | 18.26 | 7.91 |
| 2025-01-29 | XNCR | -3.54 | 18.26 | 7.91 |
| 2025-01-30 | XNCR | -3.54 | 18.26 | 7.91 |
| 2025-01-31 | XNCR | -3.54 | 18.26 | 7.91 |
| 2025-02-03 | XNCR | -3.54 | 18.20 | 7.91 |
| 2025-02-04 | XNCR | -3.54 | 18.20 | 7.91 |
| 2025-02-05 | XNCR | -3.54 | 18.20 | 7.91 |
| 2025-02-06 | XNCR | -3.54 | 18.20 | 7.91 |
| 2025-02-07 | XNCR | -3.54 | 18.20 | 7.91 |
| 2025-02-10 | XNCR | -3.54 | 18.57 | 7.91 |
| 2025-02-11 | XNCR | -3.44 | 18.57 | 7.92 |
| 2025-02-12 | XNCR | -3.44 | 18.57 | 8.00 |
| 2025-02-13 | XNCR | -3.52 | 18.57 | 7.99 |
| 2025-02-14 | XNCR | -3.52 | 18.57 | 7.99 |
| 2025-02-18 | XNCR | -3.52 | 20.85 | 7.99 |
| 2025-02-19 | XNCR | -3.49 | 20.85 | 7.99 |
| 2025-02-20 | XNCR | -3.49 | 20.85 | 7.99 |
| 2025-02-21 | XNCR | -3.49 | 20.85 | 7.99 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.71
Avg. EPS Est. Current Quarter
-0.79
Avg. EPS Est. Next Quarter
-0.83
Insider Transactions
-3.49
Institutional Transactions
20.85
Beta
0.72
Average Sales Estimate Current Quarter
17
Average Sales Estimate Next Quarter
16
Fair Value
13.94
Quality Score
22
Growth Score
39
Sentiment Score
77
Actual DrawDown %
73
Max Drawdown 5-Year %
-70.9
Target Price
32.91
P/E
Forward P/E
PEG
P/S
12.93
P/B
1.52
P/Free Cash Flow
37.75
EPS
-3.2
Average EPS Est. Cur. Y
-3.68
EPS Next Y. (Est.)
-3.09
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-232.77
Relative Volume
0.74
Return on Equity vs Sector %
-46.6
Return on Equity vs Industry %
-31
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
Xencor, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 280
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
stock quote shares XNCR – Xencor Inc Stock Price stock today
news today XNCR – Xencor Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch XNCR – Xencor Inc yahoo finance google finance
stock history XNCR – Xencor Inc invest stock market
stock prices XNCR premarket after hours
ticker XNCR fair value insiders trading